Concepts (87)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 4 | 2023 | 131 | 2.930 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2023 | 19 | 1.760 |
Why?
|
| Adenocarcinoma | 3 | 2022 | 301 | 1.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 401 | 1.400 |
Why?
|
| Neoplasms | 4 | 2022 | 611 | 1.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2023 | 196 | 0.790 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 16 | 0.670 |
Why?
|
| Indoles | 1 | 2019 | 58 | 0.670 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 90 | 0.650 |
Why?
|
| Immunotherapy | 1 | 2018 | 69 | 0.640 |
Why?
|
| Organ Transplantation | 1 | 2018 | 65 | 0.630 |
Why?
|
| Melanoma | 1 | 2018 | 148 | 0.600 |
Why?
|
| Dendritic Cells | 1 | 2014 | 61 | 0.470 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 179 | 0.430 |
Why?
|
| Humans | 16 | 2023 | 29123 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 337 | 0.430 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 206 | 0.410 |
Why?
|
| Prognosis | 4 | 2021 | 1362 | 0.400 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2021 | 32 | 0.380 |
Why?
|
| Middle Aged | 9 | 2021 | 10834 | 0.370 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 436 | 0.350 |
Why?
|
| Adult | 6 | 2022 | 8426 | 0.350 |
Why?
|
| Treatment Outcome | 4 | 2021 | 3101 | 0.340 |
Why?
|
| African Americans | 1 | 2015 | 1373 | 0.310 |
Why?
|
| Male | 9 | 2021 | 17815 | 0.290 |
Why?
|
| Female | 9 | 2021 | 18173 | 0.290 |
Why?
|
| Aged | 8 | 2022 | 9492 | 0.280 |
Why?
|
| Retrospective Studies | 3 | 2022 | 3112 | 0.260 |
Why?
|
| Mucin 5AC | 1 | 2023 | 3 | 0.230 |
Why?
|
| Pancreas | 1 | 2023 | 79 | 0.220 |
Why?
|
| Survival Analysis | 2 | 2021 | 440 | 0.210 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2021 | 5 | 0.210 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 25 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 18 | 0.200 |
Why?
|
| Pancreatectomy | 1 | 2021 | 29 | 0.190 |
Why?
|
| Malnutrition | 1 | 2020 | 17 | 0.190 |
Why?
|
| United States | 2 | 2022 | 3632 | 0.190 |
Why?
|
| Risk Factors | 2 | 2021 | 3537 | 0.190 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 14 | 0.190 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 167 | 0.180 |
Why?
|
| Camptothecin | 1 | 2020 | 48 | 0.180 |
Why?
|
| Treatment Failure | 1 | 2020 | 159 | 0.180 |
Why?
|
| Deoxycytidine | 1 | 2020 | 63 | 0.180 |
Why?
|
| Fluorouracil | 1 | 2020 | 73 | 0.180 |
Why?
|
| Esophagogastric Junction | 1 | 2019 | 7 | 0.180 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 33 | 0.170 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 45 | 0.170 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 199 | 0.170 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 34 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 77 | 0.170 |
Why?
|
| Administration, Oral | 1 | 2019 | 169 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2019 | 103 | 0.160 |
Why?
|
| Smad4 Protein | 1 | 2017 | 1 | 0.150 |
Why?
|
| Loss of Heterozygosity | 1 | 2017 | 17 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 641 | 0.150 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2109 | 0.140 |
Why?
|
| Drug Therapy | 1 | 2015 | 16 | 0.140 |
Why?
|
| Urologic Neoplasms | 1 | 2015 | 11 | 0.140 |
Why?
|
| Cisplatin | 1 | 2015 | 69 | 0.130 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2015 | 65 | 0.130 |
Why?
|
| Quality of Life | 1 | 2020 | 816 | 0.130 |
Why?
|
| Geriatric Assessment | 3 | 2022 | 355 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2017 | 208 | 0.130 |
Why?
|
| Mutation | 1 | 2017 | 466 | 0.120 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 3719 | 0.120 |
Why?
|
| Cystectomy | 1 | 2015 | 102 | 0.120 |
Why?
|
| Registries | 2 | 2022 | 278 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 1362 | 0.070 |
Why?
|
| Myeloablative Agonists | 1 | 2021 | 2 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 83 | 0.050 |
Why?
|
| Alabama | 1 | 2020 | 27 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2020 | 68 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2020 | 65 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2020 | 83 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2022 | 709 | 0.050 |
Why?
|
| Health Status | 1 | 2022 | 368 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2019 | 70 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 1119 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 898 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 525 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 417 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2017 | 6 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2017 | 30 | 0.040 |
Why?
|
| DNA, Neoplasm | 1 | 2017 | 58 | 0.040 |
Why?
|
| Cell Nucleus | 1 | 2017 | 105 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2015 | 58 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 795 | 0.030 |
Why?
|